Stilla Technologies Partners with Niba Labs to Accelerate Development of Advanced Digital PCR Assays for Cell and Gene Therapy, Strengthen Industry Research, and Expand Analytical Testing

Paris – September 17, 2024 –Stilla Technologies, a leader in digital PCR (dPCR) solutions, is pleased to announce a strategic partnership with Niba Labs, an expert laboratory specializing in developing and testing digital PCR assays for gene therapy product.

This collaboration will focus on the development of advanced digital PCR assays tailored to the needs of the gene therapy market. The Crystal Digital PCR® assays leveraging the Crystal Flex Probes technology will contribute to the scientific community by providing new solutions for viral vector characterization and gene therapy product optimization. 

Thanks to the Nio™ Digital PCR system’s 7-color multiplexing and Crystal Digital PCR® technology, combined with Niba Labs’ advanced assays, this partnership will push the boundaries of digital PCR assay multiplexing. By partitioning samples into thousands of droplet crystals and using up to seven fluorescence channels, researchers can simultaneously analyze a broad spectrum of genetic targets with unprecedented precision, accelerating advancements in gene therapy research and manufacturing processes. 

“Our partnership with Niba Labs marks a pivotal step forward in delivering greater value to our customers. Together, we’re setting a new standard in cell and gene therapy, and we’re excited about the opportunities this collaboration will unlock for the future,” says Rémi Dangla, Chief Executive Officer at Stilla Technologies.” 

Stilla Technologies digital PCR platforms will be integrated with Niba Labs’ expertise in assay development to create cutting-edge solutions that enable researchers and clinicians to better characterize and evaluate gene therapy vectors.  

About Stilla Technologies 

Stilla Technologies is the digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking solutions, include the industry’s first digital PCR systems to feature three, six, and seven fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China and throughout EMEA. To learn more, visit www.stillatechnologies.com. 

About Niba Labs

Niba Labs is an expert laboratory for digital PCR assay development and testing, focusing on addressing the analytical needs and challenges of gene therapy products. Niba Labs offers state-of-the-art, platform-independent simplex or multiplex dPCR assay development for absolute quantification of target sequences or sequence integrity testing, respectively. Furthermore, a proprietary multiplex dPCR assay platform NibaPlex® allows the expedition of custom development of advanced multiplex assays that can help investigate the sequence integrity of target viral vector genomes. To learn more, please visit www.niba-labs.com.